Products

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in Russia and CIS region. FarmaMondo to manage access to Spectrila® for patients with acute lymphoblastic leukemia in Russia, Georgia, Azerbaijan, Kyrgyzstan, Uzbekistan, Moldova. Spectrila® has been...

Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung cancer in a trial whose results were published last Monday. The benefit extended across PD-L1-positive patients in the study, regardless of their level of PD-L1 expression.  Keytruda is the first...

AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR) mutations. Tagrisso is already approved in the US as a second-line treatment for this subgroup of lung cancer patients, whose disease...

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin® via a Managed Access Program for targeted Healthcare Providers in Russia and CIS region. FarmaMondo to manage access to Empressin for patients with septic shock in Russia, Belarus, Kazakhstan,...

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by EUSA Pharma to exclusively distribute Qarziba® via a Managed Access Program for targeted Healthcare Providers in Russia and CIS region. FarmaMondo to manage access to Qarziba® for patients with high risk neuroblastoma in Russia, Belarus,...

FarmaMondo approves Normokineztine in Russian Federation for Huntington disease patients. The product, license to FarmaMondo from AOP Orphan, has been approved as the sole indicated therapy currently available for Russian patients suffering from the indicated disease. FarmaMondo will launch the product in H1 2016 through...

FarmaMondo announces the approval of Ellanse, an innovative product in the esthetic segment, by the Taiwan local regulatory body – TFDA – as a medical device class II. The product was licensed to FarmaMondo on an exclusive basis for certain markets and has been approved as...